Technology ID
TAB-2740
Multi-Antigenic Peptide(s) Vaccine and Immunogen for Conferring Streptococcus pneumoniae Immunity
E-Numbers
E-248-2013-1
Lead Inventor
Ades, Edwin (CDC)
Co-Inventors
Carlone, George (CDC)
Sampson, Jacquelyn (CDC)
Johnson, Scott (CDC)
Jue, Danny (CDC)
Applications
Vaccines
Therapeutics
Research Materials
Occupational Safety and Health
Diagnostics
Consumer Products
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Immunology
Endocrinology
Dental
Cardiology
Development Stages
Pre-Clinical (in vitro)
Development Status
- In vitro data available
- In vivo data available (animal)
Research Products
Antibodies
Lead IC
CDC
ICs
CDC
Disease caused by Streptococcus pneumoniae (pneumococcus) is an important cause of morbidity and mortality in the United States and developing countries. Pneumococcal disease is prevalent among the very young, the elderly and immunocompromised individuals. This invention is an improved, immunogenic peptide construct consisting of a combination of antigenic epitopes of the PsaA (37-kDa) protein from S. pneumoniae. In addition, the peptides of the invention have the capability of serving as specific immunogens in a subject, effectively eliciting the production of antibodies and conferring protective immunity against S. pneumoniae infection following immunognen administration.
Commercial Applications
- Development or improvement of S. pneumoniae vaccines
- Public health vaccination programs
- Clinical serodiagnostic development
Competitive Advantages
- May provide better immune protection than current, single-epitope based vaccines
- Broader spectrum of S. pneumoniae serotypes addressed
- Immunization with these peptides was shown to reduce carriage in murine studies
Licensing Contact: